Geode Capital Management
CNTX icon

Geode Capital Management’s Context Therapeutics CNTX Stock Holding History

Geode Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.58M Sell
603,767
-4,695
-0.8% -$11K ﹤0.01% 3212
2025
Q4 		$895K Sell
608,462
-115
-0% -$134 ﹤0.01% 3416
2025
Q3 		$590K Sell
608,577
-29,233
-5% -$23.7K ﹤0.01% 3557
2025
Q2 		$418K Sell
637,810
-1,409
-0.2% -$1.01K ﹤0.01% 3609
2025
Q1 		$391K Buy
639,219
+10,490
+2% +$9.13K ﹤0.01% 3637
2024
Q4 		$661K Buy
628,729
+52,830
+9% +$91.4K ﹤0.01% 3514
2024
Q3 		$1.13M Sell
575,899
-42,275
-7% -$93.8K ﹤0.01% 3312
2024
Q2 		$1.24M Buy
618,174
+517,102
+512% +$891K ﹤0.01% 3232
2024
Q1 		$140K Buy
101,072
+3,832
+4% +$4.31K ﹤0.01% 4047
2023
Q4 		$110K Hold
97,240
– – ﹤0.01% 4158
2023
Q3 		$147K Sell
97,240
-9,994
-9% -$11.3K ﹤0.01% 4103
2023
Q2 		$172K Buy
107,234
+47,666
+80% +$40.6K ﹤0.01% 4107
2023
Q1 		$33.5K Sell
59,568
-1,634
-3% -$1.24K ﹤0.01% 4607
2022
Q4 		$40K Buy
61,202
+2,530
+4% +$2.73K ﹤0.01% 4652
2022
Q3 		$65K Hold
58,672
– – ﹤0.01% 4704
2022
Q2 		$124K Buy
58,672
+8,760
+18% +$16.4K ﹤0.01% 4496
2022
Q1 		$108K Buy
+49,912
New +$105K ﹤0.01% 4634

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management's CNTX Position: Q1 2026 in Review

Geode Capital Management reduced its Context Therapeutics (CNTX) stake by 0.77% in Q1 2026, selling an estimated $11K and leaving 603,767 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3212.

Geode Capital Management first reported a position in CNTX in Q1 2022 and has held it in 17 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Geode Capital Management held 603,767 shares of Context Therapeutics worth $1.58M as of Q1 2026.
  • Geode Capital Management sold 4,695 Context Therapeutics shares in Q1 2026, an estimated $11K.
  • Context Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3212 holding.
  • Geode Capital Management first reported a position in Context Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.